Tianjin Chase Sun Pharmaceutical Group
Established in 1996, Tianjin Chase Sun Pharmaceutical Co., Ltd. is a high-tech medicine and health industry group engaged in such fields as Chinese herb preparation, Chinese medicinal granule, synthetic drugs, biotech drugs, medical apparatus and internet based therapy, and integrating investment, research and development, production and capital.
Adhering to its concept of all-round innovation, Chase Sun has established the first technology transformation center and academician work station in Tianjin, worked with scientific research institutions to establish the Innovation Alliance with enterprises as the core, and developed a trump-card series of products with independent intellectual property rights represented by “Xuebijing” injection (血必净®) and “Full Composition” formula granules (全成分®). Now Chase Sun owns 142 domestic invention patents in effect, 159 domestic utility model patents in effect, and two international invention patents in effect.
Taking “the inheritor of Chinese medicine and the leader of health industry” for the vision, Chase Sun has achieved multi-dimensional leaps and bounds through a variety of financing instruments, establishing industry clusters in many fields including raw materials production, Chinese herbal medicine planting, modernized TCM preparation, TCM formula granules, synthetic drugs, biotech drugs, medical apparatus, wearable medical products, and internet based therapy. Chase Sun has developed into a medicine and health industry group integrating investment and financing, research and development, and production and sales.
Chase Sun achieved sales revenue of RMB 3.348 billion in 2015, and paid taxation amounting RMB 633,000,000. By the beginning of 2016, Chase Sun has total assets valued at RMB 6.4 billion and a market value of RMB 20 billion, with 29 subordinate companies and more than 5,400 employees.